Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 62
Filter
1.
Int J Mol Sci ; 22(23)2021 Nov 23.
Article in English | MEDLINE | ID: mdl-34884431

ABSTRACT

Ticks, lice, flees, mosquitos, leeches and vampire bats need to prevent the host's blood coagulation during their feeding process. This is primarily achieved by injecting potent anticoagulant proteins. Basophils frequently accumulate at the site of tick feeding. However, this occurs only after the second encounter with the parasite involving an adaptive immune response and IgE. To study the potential role of basophils and mast cells in the defense against ticks and other ectoparasites, we produced anticoagulant proteins from three blood-feeding animals; tick, mosquito, and leech. We tested these anticoagulant proteins for their sensitivity to inactivation by a panel of hematopoietic serine proteases. The majority of the connective tissue mast cell proteases tested, originating from humans, dogs, rats, hamsters, and opossums, efficiently cleaved these anticoagulant proteins. Interestingly, the mucosal mast cell proteases that contain closely similar cleavage specificity, had little effect on these anticoagulant proteins. Ticks have been shown to produce serpins, serine protease inhibitors, upon a blood meal that efficiently inhibit the human mast cell chymase and cathepsin G, indicating that ticks have developed a strategy to inactivate these proteases. We show here that one of these tick serpins (IRS-2) shows broad activity against the majority of the mast cell chymotryptic enzymes and the neutrophil proteases from human to opossum. However, it had no effect on the mast cell tryptases or the basophil specific protease mMCP-8. The production of anticoagulants, proteases and anti-proteases by the parasite and the host presents a fascinating example of an arms race between the blood-feeding animals and the mammalian immune system with an apparent and potent role of the connective tissue mast cell chymases in the host defense.


Subject(s)
Antithrombin Proteins/chemistry , Basophils/enzymology , Chymases/metabolism , Mast Cells/enzymology , Parasites/metabolism , Adaptive Immunity , Animals , Chemokine CCL19/chemistry , Culicidae/metabolism , Humans , Immunoglobulin E/metabolism , Leeches/metabolism , Mice , Proteolysis , Proto-Oncogene Proteins c-sis/chemistry , Ticks/metabolism
2.
Biomaterials ; 181: 227-239, 2018 10.
Article in English | MEDLINE | ID: mdl-30092371

ABSTRACT

Glycosaminoglycan (GAG)-based hydrogels were proven highly effective to direct cell fate decisions by modulating the administration of cytokines. The sulfation pattern of the GAG component critically controls its affinity to proteins and thus governs the release of cytokines from GAG-containing gel systems. To apply this principle in the design of in situ assembling materials suitable for cell embedding and injection into tissues, we developed a platform of bio-orthogonally crosslinked star-shaped poly(ethylene glycol) (starPEG)-GAG hydrogels that display variable GAG sulfation patterns. Combining rational design for tuning the hydrogel network properties and a reaction-diffusion model for predicting transport processes within the matrices, we exemplarily applied the resulting materials for tailoring morphogenic and chemotactic gradients of platelet-derived growth factor-BB (PDGF-BB) in 3D. Conditions identified with this approach were demonstrated to effectively control the fate and morphogenesis of embedded mesenchymal stem cells (MSCs). Adjusting the sulfation patterns of glycosamnioglycans used in the preparation of in situ forming hydrogels is thus concluded to create new powerful options for modulating biomolecular signals in cell fate control, paving the way for advanced 3D cultures and precision tissue engineering.


Subject(s)
Glycosaminoglycans/chemistry , Heparin/chemistry , Hydrogels/chemistry , Mesenchymal Stem Cells/cytology , Adult , Cells, Cultured , Humans , Male , Proto-Oncogene Proteins c-sis/chemistry , Young Adult
3.
J Biomed Mater Res A ; 106(1): 115-125, 2018 Jan.
Article in English | MEDLINE | ID: mdl-28880464

ABSTRACT

Insufficient repair of the bone-to-tendon interface (BTI) with structural/compositional gradients has been a significant challenge in orthopedics. In this study, dual growth factor (platelet-derived growth factor-BB [PDGF-BB] and bone morphogenetic protein-2 [BMP-2])-immobilized polycaprolactone (PCL)/Pluronic F127 asymmetrically porous membrane was fabricated to estimate its feasibility as a potential strategy for effective regeneration of BTI injury. The growth factors immobilized (via heparin-intermediated interactions) on the membrane were continuously released for up to ∼80% of the initial loading amount after 5 weeks without a significant initial burst. From the in vivo animal study using a rat patellar tendon avulsion model, it was observed that the PDGF-BB/BMP-2-immobilized membrane accelerates the regeneration of the BTI injury, probably because of the continuous release of both growth factors (biological stimuli) and their complementary effect to create a multiphasic structure (bone, fibrocartilage, and tendon) like a native structure, as well as the role of the asymmetrically porous membrane as a physical barrier (nanopore side; prevention of fibrous tissue invasion into the defect site) and scaffold (micropore side; guidance for tissue regeneration). © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 115-125, 2018.


Subject(s)
Bone Morphogenetic Protein 2/pharmacology , Bone Regeneration/drug effects , Metal-Organic Frameworks/pharmacology , Patellar Ligament/drug effects , Proto-Oncogene Proteins c-sis/pharmacology , Animals , Becaplermin , Bone Morphogenetic Protein 2/chemistry , Disease Models, Animal , Drug Synergism , Heparin/chemistry , Imaging, Three-Dimensional , Metal-Organic Frameworks/chemistry , Poloxamer/chemistry , Polyesters/chemistry , Polyethylene Glycols/chemistry , Proto-Oncogene Proteins c-sis/chemistry , Rats , Rats, Sprague-Dawley , Surface-Active Agents/chemistry , Tissue Scaffolds
4.
ACS Comb Sci ; 19(10): 609-617, 2017 10 09.
Article in English | MEDLINE | ID: mdl-28825469

ABSTRACT

Truncation can enhance the affinity of aptamers for their targets by limiting nonessential segments and therefore limiting the molecular degrees of freedom that must be overcome in the binding process. This study demonstrated a truncation protocol relying on competitive antibody binding and the hybridization of complementary oligonucleotides, using platelet derived growth factor BB (PDGF-BB) as the model target. On the basis of the immunoassay results, an initial long aptamer was truncated to a number of sequences with lengths of 36-40 nucleotides (nt). These sequences showed apparent KD values in the picomolar range, with the best case being a 36-nt truncated aptamer with a 150-fold increase in affinity over the full-length aptamer. The observed binding energies correlated well with relative energies calculated by molecular dynamics simulations. The effect of the truncated aptamer on PDGF-BB-stimulated fibroblasts was found to be equivalent to that of the full-length aptamer.


Subject(s)
Antibodies/chemistry , Aptamers, Nucleotide/chemistry , Proto-Oncogene Proteins c-sis/chemistry , Aptamers, Nucleotide/pharmacology , Becaplermin , Binding Sites , Cell Proliferation , Fibroblasts/cytology , Fibroblasts/drug effects , Humans , Hybridization, Genetic , Molecular Dynamics Simulation , Protein Binding , Proto-Oncogene Proteins c-sis/pharmacology , Surface Plasmon Resonance/methods , Thermodynamics
5.
Biomacromolecules ; 18(10): 3131-3142, 2017 Oct 09.
Article in English | MEDLINE | ID: mdl-28850788

ABSTRACT

Hydrogel-based depots are of growing interest for release of biopharmaceuticals; however, a priori selection of hydrogel compositions that will retain proteins of interest and provide desired release profiles remains elusive. Toward addressing this, in this work, we have established a new tool for the facile assessment of protein release from hydrogels and applied it to evaluate the effectiveness of mesh size estimations on predicting protein retention or release. Poly(ethylene glycol) (PEG)-based hydrogel depots were formed by photoinitiated step growth polymerization of four-arm PEG functionalized with norbornene (PEG-norbornene, 4% w/w to 20% w/w, Mn ∼ 5 to 20 kDa) and different dithiol cross-linkers (PEG Mn ∼ 1.5 kDa or enzymatically degradable peptide), creating well-defined, robust materials with a range of mesh sizes estimated with Flory-Rehner or rubber elasticity theory (∼5 to 15 nm). A cocktail of different model proteins was released from compositions of interest, and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to facilely and quantitatively analyze temporal release profiles. Mesh size was predictive of retention of relatively large proteins and release of relatively small proteins. Proteins with diameters comparable to the mesh size, which is often the case for growth factors, were released by hindered diffusion and required experimental assessment of retention and release. With this knowledge, hydrogels were designed for the controlled release of a therapeutically relevant growth factor, PDGF-BB.


Subject(s)
Drug Liberation , Hydrogels/chemistry , Proto-Oncogene Proteins c-sis/chemistry , Becaplermin , Cross-Linking Reagents/chemistry , Hydrogels/chemical synthesis , Norbornanes/chemistry , Polyethylene Glycols/chemistry , Porosity
6.
Tissue Eng Part A ; 23(23-24): 1382-1393, 2017 12.
Article in English | MEDLINE | ID: mdl-28537482

ABSTRACT

Bone tissue engineering requires the upregulation of several regenerative stages, including a critical early phase of angiogenesis. Previous studies have suggested that a sequential delivery of platelet-derived growth factor (PDGF) to bone morphogenetic protein-2 (BMP-2) could promote angiogenic tubule formation when delivered to in vitro cocultures of human umbilical vein endothelial cells (HUVECs) and human mesenchymal stem cells (hMSCs). However, it was previously unclear that this PDGF to BMP-2 delivery schedule will result in cell migration into the scaffolding system and affect the later expression of bone markers. Additionally, a controlled delivery system had not yet been engineered for programmed sequential presentation of this particular growth factor. By combining alginate matrices with calcium phosphate scaffolding, a programmed growth factor delivery schedule was achieved. Specifically, a combination of alginate microspheres, alginate hydrogels, and a novel blend of resorbable calcium phosphate-based cement (ReCaPP) was used. PDGF and BMP-2 were sequentially released from this hybrid calcium phosphate/alginate scaffold with the desired 3-day overlap in PDGF to BMP-2 delivery. Using a three-dimensional coculture model, we observed that this sequence of PDGF to BMP-2 delivery influenced both cellular infiltration and alkaline phosphatase (ALP) expression. It was found that the presence of early PDGF delivery increased the distance of cell infiltration into the calcium phosphate/alginate scaffolding in comparison to early BMP-2 delivery and simultaneous PDGF+BMP-2 delivery. It was also observed that hMSCs expressed a greater amount of ALP+ staining in response to scaffolds delivering the sequential PDGF to BMP-2 schedule, when compared with scaffolds delivering no growth factor, or PDGF alone. Importantly, hMSCs cultured with scaffolds releasing the PDGF to BMP-2 schedule showed similar amounts of ALP staining to hMSCs cultured with BMP-2 alone, suggesting that the sequential schedule of PDGF to BMP-2 presentation promotes differentiation of hMSCs toward an osteoblast phenotype while also increasing cellular infiltration of the scaffold.


Subject(s)
Alginates , Bone Morphogenetic Protein 2 , Calcium Phosphates , Cell Differentiation/drug effects , Mesenchymal Stem Cells/metabolism , Osteoblasts/metabolism , Proto-Oncogene Proteins c-sis , Tissue Scaffolds/chemistry , Alginates/chemistry , Alginates/pharmacology , Becaplermin , Bone Morphogenetic Protein 2/chemistry , Bone Morphogenetic Protein 2/pharmacology , Calcium Phosphates/chemistry , Calcium Phosphates/pharmacology , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/pharmacology , Glucuronic Acid/chemistry , Glucuronic Acid/pharmacology , Hexuronic Acids/chemistry , Hexuronic Acids/pharmacology , Human Umbilical Vein Endothelial Cells/cytology , Human Umbilical Vein Endothelial Cells/metabolism , Humans , Mesenchymal Stem Cells/cytology , Osteoblasts/cytology , Proto-Oncogene Proteins c-sis/chemistry , Proto-Oncogene Proteins c-sis/pharmacology
7.
Biosens Bioelectron ; 95: 152-159, 2017 Sep 15.
Article in English | MEDLINE | ID: mdl-28445812

ABSTRACT

Sensitive and rapid detection of platelet-derived growth factor BB (PDGF-BB), a cancer-related protein, could help early diagnosis, treatment, and prognosis of cancers. Although some methods have been developed to detect PDGF-BB, few can provide quantitative results using an affordable and portable device that is suitable for home use or field application. In this work, we report the first use of a portable kind of personal glucose meter (PGM) combining a catalytic and molecular beacon (CAMB) system with a cation exchange reaction (CX reaction) for ultrasensitive PDGF-BB assay. It realized the amplification of the detection in three ways, including greater aptamer payload on nanoparticles, CX reaction releasing thousands of Zn2+ and the cycle by the catalyzing cleavage of 8-17 DNAzyme. In the process, with the addition of PDGF-BB into the aptasensor, the specific recognition between aptamer and protein was initiated resulting in the combination of ZnS NNC for further CX reaction to release thousands of Zn2+, which could cleave the substrate DNA in the CAMB system realizing multiple cycle. The cleaved DNA fragment was designed with invertase-labeled could convert sucrose into glucose which could be detected and quantified by PGM accompanying with the change of color of the control window from yellow to green. The enhanced signal of the PGM has a relationship with the concentration of PDGF-BB in the range of 3.16×10-16M to 3.16×10-12M, and the detection limit is 0.11fM. Moreover, the catalytic and cleavage activities of 8-17 DNAzyme can be achieved in solution; thus, no enzyme immobilization is needed for detection. The triply amplified strategy showed high selectivity, stability, and applicability for detecting the desired protein.


Subject(s)
Aptamers, Nucleotide/chemistry , Biosensing Techniques , Glucose/isolation & purification , Proto-Oncogene Proteins c-sis/isolation & purification , Becaplermin , DNA, Catalytic/chemistry , Glucose/chemistry , Gold/chemistry , Humans , Metal Nanoparticles/chemistry , Proto-Oncogene Proteins c-sis/chemistry
8.
J Hum Genet ; 62(7): 697-701, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28298627

ABSTRACT

Four causative genes, including solute carrier family 20 member 2 (SLC20A2), platelet-derived growth factor receptor b (PDGFRB), platelet-derived growth factor b (PDGFB)and xenotropic and polytropic retrovirus receptor 1 (XPR1), have been identified to cause primary familial brain calcification (PFBC). However, PDGFRB mutations seem to be quite rare and no PDGFRB mutations have been reported in Chinese PFBC patients. A total of 146 PFBC patients including 12 families and 134 sporadic patients were recruited in this study. All of them were previously tested negative for the SLC20A2. Mutational analyses of the entire exons and exon-intron boundaries of PDGFRB were carried out by direct gene sequencing. In silico analyses of the identified variants were conducted using Mutation Taster, PolyPhen-2 and Sorts Intolerant From Tolerant. Two heterozygous variants, c.3G>A and c.2209G>A, of the PDGFRB gene were revealed in two PFBC families, respectively. These two variants were not observed in 200 healthy controls. The variant c.3G>A was located in exon 2 and affected the initiation codon of the PDGFRB gene. The variant c.2209G>A resulted in amino-acid substitutions of aspartic acid to asparagine at position 737. Both of these two variants co-segregated with the disease phenotype (variant carriers in Family 1: I1, II2 and II3; variant carriers in Family 2: I2 and II8), suggesting a pathogenic impact of these variants. The prevalence of PDGFRB mutations in Chinese PFBC patients seems to be quite low, indicating that PDGFRB is not a major causative gene of PFBC in Chinese population.


Subject(s)
Asian People/genetics , Brain/pathology , Calcinosis/genetics , Mutation/genetics , Proto-Oncogene Proteins c-sis/genetics , Amino Acid Sequence , Base Sequence , Brain/diagnostic imaging , Calcinosis/diagnostic imaging , Family , Female , Humans , Male , Pedigree , Proto-Oncogene Proteins c-sis/chemistry , Xenotropic and Polytropic Retrovirus Receptor
9.
PLoS One ; 12(3): e0172499, 2017.
Article in English | MEDLINE | ID: mdl-28358890

ABSTRACT

The main limitation of tissue engineering lies in the inability to stimulate osteogenesis, angiogenesis of stem cells and broad-spectrum antimicrobial activity. However, the development of multifunctional bioactive materials with these capabilities remains a great challenge. In this study, we prepared mesoporous silica nanoparticles encapsulated with silver nanocrystals (AG-MSN) with uniform sphere size and mesopores. Platelet-derived growth factor BB (PDGF-BB) was effectively loaded in the AG-MSN mesopores (P-AG-MSN). The silicon ions (Si) released by P-AG-MSN stimulate osteogenic differentiation of bone marrow stromal cells (BMSC) by activating the alkaline phosphatase (ALP) activity of bone-related genes and increasing protein (OCN, RUNX2 and OPN) expression. Ag+ ions could be slowly released from the interior of the shell, highlighting their durable antibacterial activity. The sustained release of PDGF-BB from P-AG-MSN stimulated the angiogenic differentiation of BMSC, as indicated by the enhanced secretion of vascular endothelial growth factor (VEGF), HIF-1α, HGF and ANG-1 and protein expression. Our results show that P-AG-MSN can clearly promote BMSC osteostimulation and vascularization. This research serves as a preliminary study of the utilization of this multifunctional mixture to fabricate a new active biological scaffold that integrates BMSC osteostimulation, vascularization and bactericidal effects by 3D printing technology.


Subject(s)
Bacterial Infections/drug therapy , Hematopoietic Stem Cells/drug effects , Osteogenesis/drug effects , Proto-Oncogene Proteins c-sis/administration & dosage , Stem Cells/drug effects , Bacterial Infections/microbiology , Becaplermin , Bone Marrow Cells/drug effects , Cell Differentiation/drug effects , Gene Expression Regulation, Developmental/drug effects , Hepatocyte Growth Factor/biosynthesis , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/biosynthesis , Nanoparticles/administration & dosage , Nanoparticles/chemistry , Neovascularization, Physiologic/drug effects , Printing, Three-Dimensional , Proto-Oncogene Proteins c-sis/chemistry , Ribonuclease, Pancreatic/biosynthesis , Silicon Dioxide/chemistry , Tissue Engineering , Vascular Endothelial Growth Factor A/biosynthesis
10.
Talanta ; 158: 159-164, 2016 Sep 01.
Article in English | MEDLINE | ID: mdl-27343590

ABSTRACT

Here we describe a thrombin-linked aptamer assay (TLAA) for protein by using thrombin as an enzyme label, harnessing enzyme activity of thrombin and aptamer affinity binding. TLAA converts detection of specific target proteins to the detection of thrombin by using a DNA sequence that consists of two aptamers with the first aptamer binding to the specific target protein and the second aptamer binding to thrombin. Through the affinity binding, the thrombin enzyme is labeled on the protein target, and thrombin catalyzes the hydrolysis of small peptide substrate into product, generating signals for quantification. As a proof of principle, we show a sandwich TLAA for platelet derived growth factor BB (PDGF-BB) by using anti-PDGF-BB antibody coated on magnetic beads and an oligonucleotide containing the aptamer for PDGF-BB and the aptamer for thrombin. The binding of PDGF-BB to both the antibody and the aptamer results in labeling the complex with thrombin. We achieved detection of PDGF-BB at 16 pM. This TLAA contributes a new application of thrombin and its aptamer in bioanalysis, and shows potentials in assay developments.


Subject(s)
Aptamers, Nucleotide/chemistry , Biosensing Techniques , Proto-Oncogene Proteins c-sis/analysis , Thrombin/chemistry , Antibodies/chemistry , Becaplermin , Biological Assay , Magnetic Phenomena , Proto-Oncogene Proteins c-sis/chemistry
11.
Macromol Biosci ; 16(7): 1048-63, 2016 07.
Article in English | MEDLINE | ID: mdl-27071839

ABSTRACT

Healing of tendon ruptures represents a major challenge in musculoskeletal injuries and combinations of biomaterials with biological factors are suggested as viable option for improved healing. The standard approach of repair by conventional suture leads to incomplete healing or rerupture. Here, a new elastic type of DegraPol® (DP), a polyester urethane, is explored as a delivery device for platelet-derived growth factor-BB (PDGF-BB) to promote tendon healing. Using emulsion electrospinning as an easy method for incorporation of biomolecules within polymers, DegraPol® supports loading and release of PDGF-BB. Morphological, mechanical and delivery device properties of the bioactive DP scaffolds, as well as differences arising due to different electrospinning parameters are studied. Emulsion electrospun DP scaffolds result in thinner fibers than pure DP scaffolds and experience decreased strain at break [%], but high enough for successful surgeon handling. PDGF-BB is released in a sustained manner from emulsion electrospun DP, but not completely, with still large amount of it being inside the polymeric fibers after 30 d. In vitro studies show that the bioactive scaffolds promote tenocyte proliferation in serum free and serum(+) conditions, demonstrating the potential of this surgeon-friendly bioactive delivery device to be used for tendon repair.


Subject(s)
Polyesters/administration & dosage , Polyurethanes/administration & dosage , Proto-Oncogene Proteins c-sis/administration & dosage , Rupture/drug therapy , Tendon Injuries/drug therapy , Becaplermin , Biocompatible Materials/administration & dosage , Biocompatible Materials/chemistry , Emulsions/administration & dosage , Emulsions/chemistry , Humans , Polyesters/chemistry , Proto-Oncogene Proteins c-sis/chemistry , Plastic Surgery Procedures , Rupture/physiopathology , Rupture/surgery , Tendon Injuries/physiopathology , Tendon Injuries/surgery , Tendons/physiopathology , Tendons/surgery , Wound Healing/drug effects
12.
Anal Bioanal Chem ; 408(17): 4715-22, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27108282

ABSTRACT

We describe a sensitive aptamer-based sandwich assay for protein detection on microplate by using rolling circle amplification (RCA) coupled with thrombin catalysis. This assay takes advantage of RCA generating long DNA oligonucleotides with repeat thrombin-binding aptamer sequence, specific aptamer affinity binding to achieve multiple thrombin labeling, and enzyme activity of thrombin for signal generation. Protein target is specifically captured by antibody-coated microplate. Then, an oligonucleotide containing an aptamer for protein and a primer sequence is added to form a typical sandwich structure. Following a template encoded with complementary sequence of aptamer for thrombin, RCA reaction extends the primer sequence into a long oligonucleotide. Many thrombin molecules bind with the RCA product. Thrombin catalyzes the conversion of its chromogenic or fluorogenic peptide substrates into detectable products for final quantification of protein targets. We applied this strategy to the detection of a model protein target, platelet-derived growth factor-BB (PDGF-BB). Due to double signal amplifications from RCA and thrombin catalysis, this assay enabled the detection of PDGF-BB as low as 3.1 pM when a fluorogenic peptide substrate was used. This assay provides a new way for signal generation in RCA-involved assay through direct thrombin labeling, circumventing time-consuming preparation of enzyme-conjugate and affinity probes. This method has promise for a variety of analytical applications.


Subject(s)
Aptamers, Nucleotide/chemistry , Proteins/chemistry , Thrombin/chemistry , Becaplermin , Catalysis , Proto-Oncogene Proteins c-sis/chemistry
13.
Toxicon ; 118: 1-12, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27090013

ABSTRACT

We have previously identified two new P-III type ADAM-like snake venom metalloproteinases (SVMPs), i.e., atragin and kaouthiagin-like, from Taiwan cobra venom and determined their 3D structures with a distinct C- and I-shaped metalloproteinase/disintegrin-like/cysteine-rich (MDC) modular architecture. Herein, we investigated their functional targets to elucidate the role of cobra SVMPs in perturbing wound healing in snakebite victims. We showed that the non-RGD (Arg-Gly-Asp) C-shaped SVMP atragin binds about ten-fold stronger than the RGD-containing I-shaped SVMP kaouthiagin-like to αvß3 integrin in the surface-immobilized form. Atragin binds to αvß3 integrin through a novel interaction mode involving distal M and C domains via the RRN sequence motif in the hyper variable loop. In a cell adhesion assay, the adhesion of fibroblasts to atragin was mediated by αvß3 integrin. Furthermore, atragin inhibited wound healing and suppressed cell migration in a αvß3 integrin-dependent manner. These results, together with our previous demonstration of non-cytotoxic cobra CTX A5 in targeting αvß3 integrin, suggest that cobra venom consists of several non-RGD toxins with integrin-binding specificity that could perturb wound healing in snakebite victims.


Subject(s)
ADAM Proteins/metabolism , Elapid Venoms/enzymology , Integrin alphaVbeta3/metabolism , Reptilian Proteins/metabolism , ADAM Proteins/chemistry , ADAM Proteins/genetics , ADAM Proteins/isolation & purification , Amino Acid Motifs , Animals , Becaplermin , Cell Adhesion , Cell Movement , Elapidae , Humans , Immobilized Proteins/chemistry , Immobilized Proteins/genetics , Immobilized Proteins/metabolism , Integrin alphaVbeta3/chemistry , Integrin alphaVbeta3/genetics , Ligands , Mice , Molecular Docking Simulation , NIH 3T3 Cells , Peptide Fragments/chemistry , Peptide Fragments/genetics , Peptide Fragments/isolation & purification , Peptide Fragments/metabolism , Protein Interaction Domains and Motifs , Proto-Oncogene Proteins c-sis/chemistry , Proto-Oncogene Proteins c-sis/genetics , Proto-Oncogene Proteins c-sis/metabolism , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Reptilian Proteins/chemistry , Reptilian Proteins/genetics , Reptilian Proteins/isolation & purification , Solubility , Surface Plasmon Resonance , Taiwan
14.
Biomater Sci ; 4(5): 819-25, 2016 May 26.
Article in English | MEDLINE | ID: mdl-27010034

ABSTRACT

Platelets contain an abundance of growth factors that mimic the composition of the wound healing milieu, and platelet-derived VEGF in particular can negatively influence wound healing if unregulated. Here, we sought to capture and regulate the activity of VEGF factor from human platelets using poly(ethylene glycol) microspheres. In this communication, we demonstrate that platelet freeze/thaw produced significantly higher levels of Vascular Endothelial Growth Factor (VEGF) than either calcium chloride treatment, protease activated receptor 1 activating peptide (PAR1AP) treatment, or thrombin treatment. PEG microspheres containing a VEGF-binding peptide (VBP), derived from VEGFR2, sequestered VEGF from platelet concentrate, prepared via freeze/thaw, and reduced the bioactivity of platelet concentrate in HUVEC culture, which suggests that VBP microspheres sequestered and reduced the activity of VEGF from patient-derived platelets. Here, we demonstrate the ability of VEGF sequestering microspheres to regulate the activity of VEGF derived from a growth factor-rich autologous human blood product.


Subject(s)
Blood Platelets/metabolism , Platelet Activation , Signal Transduction , Vascular Endothelial Growth Factor A/chemistry , Becaplermin , Blood Platelets/chemistry , Cells, Cultured , Freezing , Human Umbilical Vein Endothelial Cells/drug effects , Humans , Microspheres , Peptides/chemistry , Polyethylene Glycols/chemistry , Protein Binding , Proto-Oncogene Proteins c-sis/chemistry , Thrombin/chemistry , Transforming Growth Factor beta1/chemistry , Vascular Endothelial Growth Factor Receptor-2/chemistry
15.
FEBS Lett ; 590(1): 101-9, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26787464

ABSTRACT

Pulmonary arterial hypertension (PAH) is characterized by excessive pulmonary arterial smooth muscle cells (PASMCs) growth, partially in response to PDGF-BB but whether this is dependent on ß-catenin (ßC) activation is unclear. Compared to healthy cells, PAH PASMCs demonstrate higher levels of proliferation both at baseline and with PDGF-BB that correlate with GSK3ß dependent ßC activation. We show that ßC knockdown but not Wnt5a stimulation reduces PDGF-BB dependent growth and normalizes PAH PASMCs proliferation. These findings support that cross-talk between PDGF and Wnt signaling modulates PASMC proliferation and suggest that ßC targeted therapies could treat abnormal vascular remodeling in PAH.


Subject(s)
Familial Primary Pulmonary Hypertension/metabolism , Glycogen Synthase Kinase 3/metabolism , Muscle, Smooth, Vascular/metabolism , Proto-Oncogene Proteins c-sis/metabolism , Pulmonary Artery/metabolism , Wnt Signaling Pathway , beta Catenin/agonists , Active Transport, Cell Nucleus/drug effects , Anticoagulants/pharmacology , Becaplermin , Cell Proliferation/drug effects , Cells, Cultured , Familial Primary Pulmonary Hypertension/pathology , Gene Expression Regulation/drug effects , Genes, Reporter/drug effects , Glycogen Synthase Kinase 3 beta , Humans , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/pathology , Phosphorylation/drug effects , Promoter Regions, Genetic/drug effects , Protein Processing, Post-Translational/drug effects , Proto-Oncogene Proteins/antagonists & inhibitors , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-sis/chemistry , Proto-Oncogene Proteins c-sis/pharmacology , Pulmonary Artery/cytology , Pulmonary Artery/drug effects , Pulmonary Artery/pathology , RNA Interference , Recombinant Proteins/metabolism , Recombinant Proteins/pharmacology , Wnt Proteins/antagonists & inhibitors , Wnt Proteins/genetics , Wnt Proteins/metabolism , Wnt Signaling Pathway/drug effects , Wnt-5a Protein , beta Catenin/antagonists & inhibitors , beta Catenin/genetics , beta Catenin/metabolism
16.
J Biomed Mater Res A ; 104(2): 388-96, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26414915

ABSTRACT

Development of hybrid scaffolds with synergistic combination of growth factor is a promising approach to promote early in vivo wound repair and tissue regeneration. Here, we show the rapid wound healing in Wistar albino rats using biomimetic collagen-poly(dialdehyde) guar gum based hybrid porous scaffolds covalently immobilized with platelet derived growth factor-BB. The immobilized platelet derived growth factor in the hybrid scaffolds not only enhance the total protein, collagen, hexosamine, and uronic acid contents in the granulation tissue but also provide stronger tissues. The wound closure analysis reveal that the complete epithelialization period is 15.4 ± 0.9 days for collagen-poly(dialdehyde) guar gum-platelet derived growth factor hybrid scaffolds, whereas it is significantly higher for control, collagen, collagen- poly(dialdehyde) guar gum and povidine-iodine treated groups. Further, the histological evaluation shows that the immobilized platelet derived growth factor in the hybrid scaffolds induced a more robust cellular and vascular response in the implanted site. Hence, we demonstrate that the collagen-poly(dialdehyde) guar gum hybrid scaffolds loaded with platelet derived growth factor stimulates chemotactic effects in the implanted site to promote rapid tissue regeneration and wound repair without the assistance of antibacterial agents.


Subject(s)
Biomimetic Materials/chemistry , Proto-Oncogene Proteins c-sis/pharmacology , Tissue Engineering/methods , Tissue Scaffolds/chemistry , Wound Healing/drug effects , Animals , Becaplermin , Humans , Immobilized Proteins/chemistry , Immobilized Proteins/pharmacology , Male , Porosity , Proto-Oncogene Proteins c-sis/chemistry , Rats , Rats, Wistar
17.
J Tissue Eng Regen Med ; 10(5): E275-85, 2016 05.
Article in English | MEDLINE | ID: mdl-23723146

ABSTRACT

Controlled delivery of growth factors from biodegradable biomatrices could accelerate and improve impaired wound healing. The study aim was to determine whether platelet-derived growth factor AB (PDGF.AB) with a transglutaminase (TG) crosslinking substrate site released from a fibrin biomatrix improves wound healing in severe thermal injury. The binding and release kinetics of TG-PDGF.AB were determined in vitro. Third-degree contact burns (dorsum of Yorkshire pigs) underwent epifascial necrosectomy 24 h post-burn. Wound sites were covered with autologous meshed (3:1) split-thickness skin autografts and either secured with staples or attached with sprayed fibrin sealant (FS; n = 8/group). TG-PDGF.AB binds to the fibrin biomatrix using the TG activity of factor XIIIa, and is subsequently released through enzymatic cleavage. Three doses of TG-PDGF.AB in FS (100 ng, 1 µg and 11 µg/ml FS) were tested. TG-PDGF.AB was bound to the fibrin biomatrix as evidenced by western blot analysis and subsequently released by enzymatic cleavage. A significantly accelerated and improved wound healing was achieved using sprayed FS containing TG-PDGF.AB compared to staples alone. Low concentrations (100 ng-1 µg TG-PDGF.AB/ml final FS clot) demonstrated to be sufficient to attain a nearly complete closure of mesh interstices 14 days after grafting. TG-PDGF.AB incorporated in FS via a specific binding technology was shown to be effective in grafted third-degree burn wounds. The adhesive properties of the fibrin matrix in conjunction with the prolonged growth factor stimulus enabled by this binding technology could be favourable in many pathological situations associated with wound-healing disturbances. Copyright © 2013 John Wiley & Sons, Ltd.


Subject(s)
Burns/drug therapy , Extracellular Matrix/chemistry , Fibrin , Platelet-Derived Growth Factor , Proto-Oncogene Proteins c-sis , Wound Healing/drug effects , Animals , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/pharmacokinetics , Delayed-Action Preparations/pharmacology , Fibrin/chemistry , Fibrin/pharmacokinetics , Fibrin/pharmacology , Platelet-Derived Growth Factor/chemistry , Platelet-Derived Growth Factor/pharmacokinetics , Platelet-Derived Growth Factor/pharmacology , Proto-Oncogene Proteins c-sis/chemistry , Proto-Oncogene Proteins c-sis/pharmacokinetics , Proto-Oncogene Proteins c-sis/pharmacology , Swine
18.
Molecules ; 20(11): 20832-40, 2015 Nov 23.
Article in English | MEDLINE | ID: mdl-26610452

ABSTRACT

G-quadruplexes (G4s) are noncanonical DNA/RNA structures formed by guanine-rich sequences. Recently, G4s have been found not only in aptamers but also in the genomic DNA and transcribed RNA. In this study, we identified new RNA oligonucleotides working as aptamers by focusing on G4-forming RNAs located within the pre-mRNA. We showed that the G4 in the 5' UTR and first intron of VEGFA bound to the protein encoded in VEGFA gene, VEGF165, with high affinity. Moreover, G4-forming RNAs located within the PDGFA and the PDGFB introns bound to PDGF-AA and PDGF-BB, respectively, indicating that G4 in the pre-mRNA could be an aptamer. It had been reported that the putative G4-forming RNA sequences are located in some parts of most genes, thus our strategy for aptamer identification could be applicable to other proteins. It has been reported that some G4-forming RNAs in 5' UTRs are involved in translation control; however, G4-forming excised intronic RNA function has not been revealed previously. Therefore, these findings could not only contribute to the identification of RNA aptamers but also provide new insights into the biological functioning of G4-forming RNAs located within intronic RNA sequences.


Subject(s)
G-Quadruplexes , Oligoribonucleotides/chemistry , Oligoribonucleotides/metabolism , RNA Precursors/chemistry , RNA Precursors/metabolism , RNA-Binding Proteins/metabolism , Circular Dichroism , Humans , Nucleic Acid Conformation , Platelet-Derived Growth Factor/chemistry , Platelet-Derived Growth Factor/genetics , Protein Binding , Proto-Oncogene Proteins c-sis/chemistry , Proto-Oncogene Proteins c-sis/genetics , RNA Precursors/genetics , Surface Plasmon Resonance , Transcription, Genetic , Vascular Endothelial Growth Factor A/chemistry , Vascular Endothelial Growth Factor A/genetics
19.
J Mol Biol ; 427(24): 3921-34, 2015 Dec 04.
Article in English | MEDLINE | ID: mdl-26463591

ABSTRACT

Members of the receptor tyrosine kinases (RTKs) regulate important cellular functions such as cell growth and migration, which are key steps in angiogenesis, in organ morphogenesis and in the unregulated states, cancer formation. One long-standing puzzle regarding RTKs centers on how the extracellular domain (ECD), which detects and binds to growth factors, is coupled with the intracellular domain kinase activation. While extensive structural works on the soluble portions of RTKs have provided critical insights into RTK structures and functions, lack of a full-length receptor structure has hindered a comprehensive overview of RTK activation. In this study, we successfully purified and determined a 27-Å-resolution structure of PDGFRß [a full-length human platelet-derived growth factor receptor], in complex with its ligand PDGF-B. In the ligand-stimulated complex, two PDGFRßs assemble into a dimer via an extensive interface essentially running along the full-length of the receptor, suggesting that the membrane-proximal region, the transmembrane helix and the kinase domain of PDGFRß are involved in dimerization. Major structural differences are seen between the full-length and soluble ECD structures, rationalizing previous experimental data on how membrane-proximal domains modulate receptor ligand-binding affinity and dimerization efficiency. Also, in contrast to the 2-fold symmetry of the ECD, the intracellular kinase domains adopt an asymmetric dimer arrangement, in agreement with prior observations for the closely related KIT receptor. In essence, the structure provides a first glimpse into how platelet-derived growth factor receptor ECD, upon ligand stimulation, is coupled to its intracellular domain kinase activation.


Subject(s)
Proto-Oncogene Proteins c-sis/chemistry , Receptor, Platelet-Derived Growth Factor beta/chemistry , Catalytic Domain , HEK293 Cells , Humans , Microscopy, Electron , Models, Molecular , Protein Binding , Protein Structure, Quaternary , Proto-Oncogene Proteins c-sis/ultrastructure , Receptor, Platelet-Derived Growth Factor beta/ultrastructure , Staining and Labeling
20.
Biomed Mater ; 10(4): 045008, 2015 Jul 23.
Article in English | MEDLINE | ID: mdl-26201844

ABSTRACT

The aim of this work was to study the bone repair induced by bone morphogenetic protein-2 (BMP-2), rat mesenchymal stem cells (rMSCs), and platelet-derived growth factor (PDGF-BB) incorporated in a macroporous beta-tricalcium phosphate (ß-TCP) system fabricated by robocasting, and to identify the most beneficial combination in a critical rat calvaria defect. BMP-2 was formulated in microspheres to provide a prolonged, local concentration, whereas PDGF-BB, which acts during the initial stage of defect repair, was incorporated in a thin layer of crosslinked alginate. Approximately 80% of PDGF-BB and 90% of BMP-2 were released into the defect during the first 2 d and 3 weeks, respectively. Histological analyses indicated a minor synergistic effect in the BMP-2-MSC groups. In contrast, significant antagonism was found with combined BMP-2 and PDGF-BB defect treatment. The high-grade repair induced by BMP-2 rules out any advantage from combining BMP-2 with PDGF-BB or MSCs, at least with this scaffold and defect model.


Subject(s)
Bone Morphogenetic Protein 2/administration & dosage , Calcium Phosphates/chemistry , Mesenchymal Stem Cell Transplantation/instrumentation , Proto-Oncogene Proteins c-sis/administration & dosage , Skull Fractures/therapy , Tissue Scaffolds , Animals , Becaplermin , Bone Morphogenetic Protein 2/chemistry , Bone Substitutes/chemical synthesis , Cells, Cultured , Combined Modality Therapy/instrumentation , Combined Modality Therapy/methods , Drug Implants/administration & dosage , Drug Therapy, Combination , Equipment Design , Equipment Failure Analysis , Male , Porosity , Proto-Oncogene Proteins c-sis/chemistry , Rats , Rats, Sprague-Dawley , Skull Fractures/pathology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...